Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed,
and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government
operating status and resumption of normal operations can be found at opm.gov.
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00431340
(Terminated due to dose limiting toxicity)
This open-label study will assess anti-tumor activity and safety of belinostat in combination with bortezomib (Velcade®) in multiple myeloma patients refractory to or relapsed from at least one prior bortezomib-containing regimen. Subjects will be administered both PXD101 and bortezomib on the same days: i.e. days 1, 4, 8, and 11 of a 3-week cycle, for up to 8 cycles.
Objective response rate of belinostat administered in combination with bortezomib in multiple myeloma subjects who are refractory to or have relapsed from at least one prior bortezomib-containing regimen.
Safety of belinostat plus bortezomib.
Secondary Outcome Measures
Duration of response, time to response (TTR), and time to progression (TTP).
Effect on biomarkers of bone metabolism. Effect on disease-related bone pain.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosis of multiple myeloma.
Status of refractory to or relapsed from at least one prior bortezomib-containing regimen.
Age >= 18 years.
Karnofsky performance status >= 60%
Acceptable liver function:
Bilirubin =< 1.5 x ULN (upper limit of normal)
Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3 x ULN
Acceptable hematologic status:
Absolute Neutrophil Count (ANC) >= 1.5 x 109/L
Platelet count >= 100 x 109/L
Hemoglobin >= 9 g/dL
Coagulation status PT-INR/PTT =< 1.5 x ULN or in the therapeutic range if on anticoagulation therapy. (PT-INR/PTT= prothrombin - international normalized ratio / prothrombin time)
Serum potassium within normal range.
Estimated life expectancy greater than 3 months.
Signed, written IRB (institutional Review Board)-approved informed consent.
Non-secretory multiple myeloma or symptomatic amyloidosis.
Hypersensitivity to bortezomib, boron, or mannitol.
Less than 4 weeks since prior chemotherapy, radiotherapy, endocrine therapy, or immunotherapy, except if disease is rapidly progressing.
Less than 4 weeks since prior use of other investigational agents.
Serious concomitant systemic disorders (e.g. active infection).
Significant cardiovascular disease.
Marked baseline prolongation of QT/QTc (corrected QT interval)interval.
Central nervous system disorders requiring neuroleptics / anti-convulsants.
Peripheral sensory neuropathy of ≥ Grade 2
Renal insufficiency defined as a creatinine clearance of < 30 ml/min.
Non-willingness to use effective contraceptive methods for patients of child-bearing age / potential.
Pregnant or breast-feeding women.
Known HIV positivity.
Prior treatment with belinostat (PXD101), or any other HDAC (histone deacetylase) inhibitor.
Altered mental status which precludes an understanding of the Informed Consent Document.